Photodynamic therapy has long attracted interest because of its fundamentally noninvasive character: a photosensitizing compound is delivered to the tumor, light of a specific wavelength is applied, and photochemical reactions produce reactive oxygen species that kill cancer cells through oxidative stress while largely sparing surrounding healthy tissue. Yet the effectiveness of the approach depends critically on where the photosensitizer accumulates inside the cell. Directing these molecules to mitochondria, the cell’s energy factories, is a common strategy, but mitochondrial accumulation can trigger unwanted toxicity even in the dark, before any light is applied. Targeting the nucleus carries the risk of DNA damage and mutagenesis. The endoplasmic reticulum, the membrane-bound organelle responsible for protein synthesis, folding, transport, and calcium homeostasis, has emerged as a compelling alternative. Damage to this organelle induces a cellular alarm state known as ER stress, which can drive cells toward death while avoiding some of the liabilities of the other targets.

The research team selected the quinoxalinone scaffold as the core chromophore of their photosensitizer, a choice grounded in its high molar absorption coefficient and bright fluorescent emission. To push the absorption toward longer wavelengths, which is essential for achieving useful tissue penetration in treating deep-seated tumors, the chemists extended the pi-conjugation of the scaffold by attaching thiophene and dicyanovinyl groups. This electron push-pull design lowers the energy gap between excited singlet and triplet states, facilitating intersystem crossing, the photophysical process through which a photosensitizer enters the long-lived triplet state needed to transfer energy to oxygen and generate singlet oxygen, the most cytotoxic of the reactive oxygen species. Spectroscopic confirmation by proton and carbon-13 nuclear magnetic resonance verified the chemical structure, and ultraviolet-visible measurements showed broad absorption spanning from 300 to 700 nanometers, an unusually wide window for harvesting light.

Because the resulting photosensitizer is hydrophobic, the researchers packaged it into nanoparticles built from human serum albumin, the most abundant protein in human plasma and a natural carrier for hydrophobic molecules. The albumin was further decorated with a reversibly activated cell-penetrating peptide, or RACR, attached through a thiol-ene click reaction. This peptide is designed to switch on under tumor-specific conditions such as altered enzyme expression or acidity, enhancing accumulation within cancer cells while limiting off-target toxicity to normal tissues. The resulting particles measured roughly 80 nanometers in hydrodynamic diameter by dynamic light scattering, with a narrow polydispersity index of 0.23 and a mildly negative surface charge of about minus 11.6 millivolts. Transmission electron microscopy confirmed uniform spherical morphology. Loading efficiency reached 26.7 percent, while encapsulation efficiency climbed to 89.2 percent, and the nanoparticles remained stable over ten days in both phosphate-buffered saline and cell culture medium.

The particles’ light-harvesting and energy-transfer performance proved impressive. When excited, Qui-PS NPs emitted near-infrared fluorescence centered at 830 nanometers, an emission band useful for tracking the particles in living tissue. More importantly, their singlet oxygen generation efficiency was quantified at 61.7 percent using a standard chemical probe, 9,10-anthracenediyl-bis(methylene)dimalonic acid, which degrades upon reaction with singlet oxygen. Under laser irradiation the nanoparticles decomposed this probe far more rapidly than the free photosensitizer under identical conditions, indicating that confinement within the albumin nanoparticle substantially amplifies the photodynamic output.

In cell culture with MCF-7 human breast cancer cells, the nanoparticles were internalized efficiently, with fluorescence detectable as early as two hours after incubation and increasing steadily thereafter, a pattern confirmed quantitatively by flow cytometry. Colocalization experiments using a green fluorescent ER tracker demonstrated that the red-emitting nanoparticles congregated precisely in the endoplasmic reticulum, validating the targeting strategy. When illuminated with a 530-nanometer laser at 100 milliwatts per square centimeter for five minutes, the nanoparticles killed the cancer cells in a dose-dependent manner with a half-maximal inhibitory concentration of 3.2 micrograms per milliliter, markedly lower than that of the free photosensitizer. Crucially, in the dark both the free molecule and the nanoparticles were essentially nontoxic, confirming the biocompatibility profile that makes light-triggered therapy so attractive.

The team then moved to animal studies, injecting the nanoparticles intravenously into nude mice bearing MCF-7 tumor xenografts at a dose of 20 milligrams per kilogram. In vivo fluorescence imaging showed tumor accumulation peaking at two hours after injection and remaining high for up to twelve hours, consistent with enhanced permeability and retention, the phenomenon by which leaky tumor vasculature preferentially accumulates nanoparticles. Inductively coupled plasma mass spectrometry of dissected organs revealed that the photosensitizer concentrated mainly in the tumor and the liver, a biodistribution profile the authors flag as requiring attention to hepatic effects during treatment. The therapeutic outcome, however, was striking. While untreated control tumors grew to approximately 1400 cubic millimeters over twenty-four days, mice receiving the nanoparticles followed by laser irradiation showed almost complete suppression of tumor growth for the entire observation period, significantly outperforming the free photosensitizer under the same light. Body weights were unchanged across all groups, and histological staining of excised tumors revealed extensive necrosis and drastically reduced cell density in the treated animals.

Beyond direct tumor destruction, the treatment reshaped the immune landscape of the tumors. Flow cytometric analysis of tumor-infiltrating lymphocytes showed that the fraction of cytotoxic CD8-positive T cells rose to 52.7 percent in mice treated with the nanoparticles, compared with 30.1 percent in controls, while helper CD4-positive T cells increased to 48.1 percent from 17.2 percent. Cytokine profiling added a nuanced picture: the immunostimulatory interleukins IL-10 and IL-12 were significantly elevated in tumor tissue, whereas the pro-inflammatory TNF-alpha and IL-6 were significantly reduced. The authors argue that this counterintuitive profile reflects a genuine remodeling of the tumor immune microenvironment rather than a simple inflammatory surge. Excessive TNF-alpha and IL-6, they note, can foster a chronic inflammatory milieu that promotes tumor proliferation, invasion, and immune escape, while IL-12 drives dendritic cell maturation, M1 macrophage polarization, and cytotoxic T cell infiltration, the very processes needed to convert immunologically cold tumors, which are poorly infiltrated by T lymphocytes, into hot ones susceptible to immune attack. Moderate IL-10 elevation, meanwhile, maintains immune homeostasis and protects healthy tissue. Additional analysis showed that the treatment arrested tumor cells in the G0/G1 phase of the cell cycle, blocking proliferation through a second, complementary mechanism.

The study is not without limitations, which the authors acknowledge candidly. The photosensitizer’s fluorescence emission falls in the visible rather than the near-infrared region between 650 and 900 nanometers, where tissue penetration is deepest. For treating deep-seated tumors, activation at visible wavelengths constrains how far the light can reach, so the team plans structural modifications to shift the emission into the near-infrared window in future iterations. Even so, the platform’s logic extends beyond this single molecule. Because the albumin nanoparticle system combines a potent chromophore, tumor-activated cell penetration, and precise organelle targeting, the researchers suggest it could serve as a carrier for other therapeutic agents as well, opening avenues for drug delivery schemes that exploit endoplasmic reticulum stress as a general vulnerability of cancer cells. As preclinical evidence goes, the demonstration that a light-activated nanoparticle can nearly halt tumor growth while simultaneously recalibrating the immune environment and leaving treated animals systemically unharmed represents a substantial step toward organelle-precise cancer therapy.

Yet, despite its specificity and non-invasiveness, conventional PDT faces substantial limitations, chiefly the inefficient delivery and premature degradation of photosensitizers en route to the tumor microenvironment. Enter liposomal nanotechnology — a revolutionary platform that encapsulates photosensitizers within nanoscale lipid bilayer vesicles, known as liposomes. These carriers not only protect photosensitive drugs from enzymatic degradation and immune clearance in the bloodstream but also leverage the enhanced permeability and retention (EPR) effect intrinsic to tumor vasculature. Consequently, liposomes facilitate heightened accumulation and retention of photosensitizers within the tumor interstitium, optimizing therapeutic efficacy while minimizing systemic toxicity.

The recent publication from the collaborative team led by Professor Heidi Abrahamse at the Laser Research Centre, University of Johannesburg, titled “Recent trends in liposomal drug efficiency of nanotechnology in photodynamic therapy for cancer,” highlights groundbreaking advances in this arena. Their experimental studies meticulously dissect the physicochemical properties, surface modifications, and controlled-release profiles of liposomal formulations engineered to surmount the biological barriers posed by the tumor microenvironment. By fine-tuning lipid composition, particle size, and surface charge, the researchers enhanced liposome stability in circulation and improved tumor-targeting specificity.

One of the cornerstone innovations discussed in the study is the development of stimuli-responsive liposomes. These smart liposomes remain quiescent during systemic circulation but undergo triggered release of photosensitizers upon encountering specific tumor-related stimuli, such as acidic pH, enzymatic activity, or even external light irradiation. This spatiotemporal precision guarantees that the active therapeutic agents are liberated exclusively within the malignant milieu, amplifying local reactive oxygen species generation while sparing non-target tissues. The findings underscore the potency of integrating nanotechnology with photomedicine to revolutionize cancer therapeutics.

Moreover, the exploration into multifunctional liposomes that co-deliver photosensitizers alongside complementary therapeutics, such as chemotherapy drugs or immunomodulators, opens exhilarating avenues for combination therapy. Such nanoplatforms can orchestrate synergistic anti-cancer effects, overcoming resistance mechanisms and enhancing overall treatment outcomes. The efficient encapsulation, protection, and targeted release capabilities of liposomes empower clinicians with unprecedented tools to customize therapies according to tumor heterogeneity and patient-specific pathophysiology.

This study also addresses crucial challenges in clinical translation, such as large-scale reproducibility, biosafety, and regulatory compliance, offering strategic insights into optimizing formulation protocols and pharmacokinetics. The liposomal PDT platform from the University of Johannesburg transcends conventional paradigms, exemplifying how a multidisciplinary approach encompassing physics, chemistry, biology, and engineering can foster innovative solutions to complex oncological problems.

The global burden of cancer necessitates continuous refinement of therapeutic modalities that maximize efficacy while curtailing adverse effects. Liposome-assisted photodynamic therapy epitomizes this goal by combining the inherent advantages of nanocarriers — biocompatibility, reduced immunogenicity, and selective tumor targeting — with the minimally invasive and spatially controlled nature of PDT. Such integration is poised to redefine the standard of care, improving patient quality of life and survival rates.

In addition, the precise mechanistic insights elucidated in this body of work shed light on intracellular trafficking pathways, endosomal escape mechanisms, and subcellular localization of photosensitizers delivered via liposomes. Understanding these molecular underpinnings enables rational design of next-generation constructs that exploit intracellular vulnerabilities of cancer cells. The enhancement of singlet oxygen generation efficacy and photostability of photosensitizers within liposomal environments further potentiates therapeutic success.

These advancements underscore the transformative potential of nanotechnology-driven photomedicine. As the field ventures into personalized cancer care, the ability to tailor liposomal PDT formulations according to tumor phenotype and genetic profiles becomes increasingly feasible. The adoption of artificial intelligence and machine learning tools to predict optimal treatment parameters and formulation architecture will further accelerate clinical implementation.

The pioneering research spearheaded by Professor Abrahamse and her multidisciplinary team serves as a testament to the power of integrating diverse scientific domains to tackle cancer’s complexity. Their efforts catalyze a paradigm shift from conventional chemotherapy and radiotherapy towards more selective, less toxic, and highly efficient treatment regimens. The ongoing evolution of liposomal nanotechnology in photodynamic therapy illuminates a future where precision oncology is not merely aspirational but a clinical reality.

While challenges remain — including long-term safety assessments, immunological impacts of repeated liposomal administration, and patient-specific delivery kinetics — the strides made in this study provide a robust framework for overcoming these obstacles. Continued interdisciplinary collaboration and technological innovation are paramount to fully realize the promise of liposome-enabled photodynamic cancer therapies.

In conclusion, the convergence of liposomal nanotechnology and photodynamic therapy heralds a new era in targeted cancer treatment. By shielding photosensitizers within intelligent lipid carriers and releasing them precisely under light activation at tumor sites, this strategy maximizes therapeutic efficiency and mitigates collateral damage. With cancer incidence steadily rising worldwide, such advancements represent hope not only for improved cure rates but also for enhancing the quality of life for millions of patients globally. The future of oncological care is brightened by these light-activated, nanoparticle-enhanced therapies that promise safer, smarter, and more effective cancer eradication.

Subject of Research: Not applicable
Article Title: Recent trends in liposomal drug efficiency of nanotechnology in photodynamic therapy for cancer
News Publication Date: 2-Feb-2026
Web References: 10.2738/foe.2026.0005
Image Credits: HIGHER EDUCATION PRESS
Keywords: Photodynamic Therapy, Liposomal Nanotechnology, Cancer Treatment, Photosensitizers, Reactive Oxygen Species, Targeted Drug Delivery, Stimuli-Responsive Liposomes, Nanomedicine, Precision Oncology, Multidisciplinary Research